CAL-05CR
Moderate to Severe Osteoarthritis Pain
Pre-clinicalActive
Key Facts
About Calosyn Pharma
Calosyn Pharma is advancing a novel, sustained-release injectable therapy, CAL-05CR, for moderate to severe osteoarthritis pain. The drug candidate is a reformulation of verapamil, a calcium channel blocker, based on foundational research linking aberrant calcium signaling to disease pathology. The company has generated promising human data and is positioned to advance into Phase 2 clinical trials, targeting a large market with significant unmet need. Calosyn is a private company led by a team with deep orthopedic clinical and pharmaceutical development expertise.
View full company profile